Third member of FDA advisory committee resigns after approval of controversial Alzheimer’s drug aducanumab

The latest resignation from Aaron Kesselheim, professor of Medicine at Harvard Medical School, is based on the decision to approve aducanumab based on clearance of beta-amyloid rather than its effectiveness in slowing or halting disease progression.

Source:

Biospace Inc.